DC-CIK细胞联合化疗治疗老年晚期非小细胞肺癌临床分析  

Clinical study of DC-CIK in combination with chemotherapy for elderly patients with advanced non-small cell lung cancer

作　　者：赵利红[1] 汪海岩[1] 赵晶[1] 张德芳[1] 

机构地区：[1]徐州医学院附属医院肿瘤科,江苏徐州221002

出　　处：《徐州医学院学报》2013年第12期880-883,共4页Acta Academiae Medicinae Xuzhou

摘　　要：目的 观察自体树突状细胞（DC）、细胞因子诱导的杀伤细胞（CIK）联合化疗对老年非小细胞肺癌患者的免疫功能、临床疗效、生活质量和毒副作用的影响.方法 选取36例DC-CIK细胞联合化疗治疗的老年晚期非小细胞肺癌患者作为联合治疗组,以同期临床特点相近的36例接受单纯化疗的患者作为单纯化疗组,比较2种方法治疗前后患者免疫功能及组间临床疗效、生活质量和毒副作用.结果 与治疗前比较：联合治疗组CD4＋升高（P=0.00）,CD8＋无明显变化（P=0.93）,CD4 ＋/CD8＋升高（P＜0.05）,自然杀伤细胞（NK细胞）升高（P＜0.05）;单纯化疗组CD4＋明显降低（P＜0.05）,CD8＋变化不明显,CD4 ＋/CD8＋降低（P＜0.05）,NK细胞降低（P＜0.05）.与单纯化疗组相比,联合治疗组的疾病控制率明显高于单纯化疗组（80.1％ vs.52.8％,P＜0.05）,体力下降、食欲降低发生率明显降低（P＜0.05）,化疗副作用（骨髓抑制、恶心呕吐、外周神经毒性）发生率明显降低（P＜0.05）.结论 与单纯化疗相比,DC-CIK细胞联合化疗治疗更安全、有效,能提高老年晚期非小细胞肺癌患者生活质量和临床缓解率.Objective To evaluate the influence of autologous dendritic cells （DCs） and cytokine induced killer （CIK） cells in combination with chemotherapy on elderly patients with advanced non- small cell lung cancer （NSCLC） in terms of immune function, clinical efficacy, life quality and side effects. Methods 36 elderly patients with advanced NSCLC were enrolled who received DC - CIK in combination with chemotherapy, while another 36 elderly advanced NSCLC patients were included as a group who were treated with chemotherapy alone. Then, a comparison of immune function before and after treatment was undergone and intergroup clinical efficacy, quality of life and side effects were ob- served. Results Compared with the values prior to treatment, the percentages of CD^8 , CD4 ＋/CD8 and NK cells were significantly higher in the combined treatment group （P 〈 0.05 ）, in contrast with remarkably reduced levels in the chemotherapy group. No significant difference was found in the percentages of CD8 ＋ in both groups before and after treatment. Furthermore, compared with the chemotherapy group, the combined therapy group presented a substantial increase in disease control rate （80.1% vs. 52.8% , P 〈 0.05） and remarkable amelioration of body weight loss, loss of appetite and chemotherapy adverse reaction （bone marrow suppression, nausea and peripheral neuropathy） （P 〈 0.05 ）. Conclusion Compared with chemotherapy alone, DC - CIK in combination with chemotherapy is safer and more effective, stimulating the improvement of quality of life and clinical remission rate for elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 晚期 老年 过继性细胞免疫治疗 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]